###begin article-title 0
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1</italic>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 101 106 <span type="species:ncbi:9606">human</span>
Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 224 231 <span type="species:ncbi:9606">patient</span>
Secreted Wnt signaling antagonists have recently been described as frequent targets of epigenetic inactivation in human tumor entities. Since gene silencing of certain Wnt antagonists was found to be correlated with adverse patient survival in cancer, we aimed at investigating a potential prognostic impact of the two Wnt antagonizing molecules WIF1 and DKK3 in breast cancer, which are frequently silenced by promoter methylation in this disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
WIF1 and DKK3 promoter methylation were assessed by methylation-specific PCR with bisulfite-converted DNA from 19 normal breast tissues and 150 primary breast carcinomas. Promoter methylation was interpreted in a qualitative, binary fashion. Statistical evaluations included two-sided Fisher's exact tests, univariate log-rank tests of Kaplan-Meier curves as well as multivariate Cox regression analyses.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 0 14 0 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 and DKK3 </italic>
###xml 155 160 155 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 333 338 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 445 450 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 533 538 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 613 618 613 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 781 785 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 837 842 837 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 972 977 972 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1060 1065 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1114 1119 1114 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 484 491 <span type="species:ncbi:9606">patient</span>
###xml 583 590 <span type="species:ncbi:9606">patient</span>
###xml 657 664 <span type="species:ncbi:9606">patient</span>
###xml 767 775 <span type="species:ncbi:9606">patients</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
###xml 1033 1041 <span type="species:ncbi:9606">patients</span>
WIF1 and DKK3 promoter methylation were detected in 63.3% (95/150) and 61.3% (92/150) of breast carcinoma samples, respectively. In normal breast tissues, WIF1 methylation was present in 0% (0/19) and DKK3 methylation in 5.3% (1/19) of samples. In breast carcinomas, WIF1 methylation was significantly associated with methylation of DKK3 (p = 0.009). Methylation of either gene was not associated with clinicopathological parameters, except for DKK3 methylation being associated with patient age (p = 0.007). In univariate analysis, WIF1 methylation was not associated with clinical patient outcome. In contrast, DKK3 methylation was a prognostic factor in patient overall survival (OS) and disease-free survival (DFS). Estimated OS rates after 10 years were 54% for patients with DKK3-methylated tumors, in contrast to patients without DKK3 methylation in the tumor, who had a favorable 97% OS after 10 years (p < 0.001). Likewise, DFS at 10 years for patients harboring DKK3 methylation in the tumor was 58%, compared with 78% for patients with unmethylated DKK3 (p = 0.037). Multivariate analyses revealed that DKK3 methylation was an independent prognostic factor predicting poor OS (hazard ratio (HR): 14.4; 95% confidence interval (CI): 1.9-111.6; p = 0.011), and short DFS (HR: 2.5; 95% CI: 1.0-6.0; p = 0.047) in breast cancer.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 105 110 <span type="species:ncbi:9606">human</span>
Although the Wnt antagonist genes WIF1 and DKK3 show a very similar frequency of promoter methylation in human breast cancer, only DKK3 methylation proves as a novel prognostic marker potentially useful in the clinical management of this disease.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 764 767 764 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 789 790 789 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1123 1127 1123 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1</italic>
###xml 1219 1220 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1221 1223 1221 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1324 1328 1324 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 1452 1454 1452 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1540 1544 1540 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1571 1573 1571 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1574 1576 1574 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 254 259 <span type="species:ncbi:9606">human</span>
###xml 1414 1422 <span type="species:ncbi:9606">patients</span>
###xml 1719 1724 <span type="species:ncbi:9606">human</span>
The most common epigenetic alteration in human cancer affecting gene expression is 5'-cytosine methylation within CpG islands in gene promoter regions [1]. Promoter methylation effectively represses RNA transcription and occurs in many genes involved in human cancer development [2]. The majority of these affected genes are potential or known tumor suppressor genes that are regulators of different cellular pathways, such as cell cycle, DNA repair, growth factor signaling or cell adhesion [3]. Wnt signaling is one of the central cellular pathways commonly disrupted in several tumor types, including breast cancer [4,5]. Unlike colorectal cancer, evidence for genetic alterations of Wnt pathway components in breast cancer, such as adenomatous polyposis coli (APC) mutations, is rare [6]. Several lines of evidence suggest that in breast cancer the Wnt signaling pathway is disrupted predominantly through epigenetic aberrations, most of all by promoter methylation of genes encoding secreted Wnt inhibitory molecules. For instance, genes encoding secreted frizzled-related proteins (SFRP) and Wnt-inhibitory factor-1 (WIF1) were previously reported as frequent targets of epigenetic inactivation in breast cancer [7-12]. In addition to this, we have recently shown that the putative Wnt signaling inhibitor Dickkopf-3 (DKK3) is functionally inactivated by promoter methylation in more than 60% of tumors from patients with invasive breast cancer [13]. Besides secreted inhibitors, two studies also reported frequent methylation of the APC gene in breast carcinomas [14,15]. Altogether, this provides strong evidence for an epigenetically disrupted and thereby activated Wnt signaling pathway in the development of human breast cancer.
###end p 11
###begin p 12
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP1 </italic>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP5 </italic>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SFRP2 </italic>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 929 931 929 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 934 939 934 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1063 1065 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1099 1101 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 325 332 <span type="species:ncbi:9606">patient</span>
###xml 461 468 <span type="species:ncbi:9606">patient</span>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 601 608 <span type="species:ncbi:9606">patient</span>
###xml 1296 1301 <span type="species:ncbi:9606">human</span>
There is increasing evidence that promoter methylation of cancer-related genes can be one of the most prevalent molecular markers for human cancer diseases [16]. The potential clinical applications of DNA-methylation biomarkers may include diagnosis of neoplasm, tumor classification, prediction of response to treatment, or patient prognosis [17]. Methylation of particular Wnt pathway genes has already been described as a potential biomarker for unfavorable patient outcome in human cancer. For instance, we have recently shown that methylation of SFRP1 as well as SFRP5 is associated with reduced patient overall survival in breast cancer [7,10]. In contrast to this, high-frequent methylation of SFRP2 was not prognostically relevant in breast cancer [9], but was shown to comprise a diagnostic value as a sensitive screening marker for the stool-based detection of colorectal cancer and premalignant colorectal lesions [18-20]. DKK3 methylation is associated with reduced DFS in acute lymphoblastic leukemia [21], and also with shorter OS in kidney cancer [22] and non-small cell lung cancer [23], as well as very recently reported with OS in gastric cancer [24]. Taken together, promoter methylation of Wnt signaling antagonists appears to provide a rich pool of novel tumor biomarkers in human cancer, potentially useful in the clinical setting by helping to improve management of this disease.
###end p 12
###begin p 13
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 472 477 472 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 542 549 <span type="species:ncbi:9606">patient</span>
###xml 562 567 <span type="species:ncbi:9606">human</span>
In the present study, we addressed the question to whether promoter methylation of two Wnt antagonist genes (WIF1 and DKK3), that were previously reported as hypermethylated in breast cancer, provides prognostically relevant information in this tumor entity. In univariate and multivariate analyses we have investigated gene methylation in a large cohort (n = 150) of invasive breast cancer specimens. We here demonstrate for the first time that DKK3 methylation, but not WIF1 methylation, is an independent prognostic factor indicating poor patient survival in human breast cancer.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient material
###end title 15
###begin p 16
###xml 822 830 822 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 1172 1174 1172 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1278 1280 1278 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1386 1388 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1566 1568 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
###xml 1399 1407 <span type="species:ncbi:9606">patients</span>
###xml 1495 1502 <span type="species:ncbi:9606">Patient</span>
Surgically resected samples were obtained from 150 unselected breast cancer patients at the Departments of Gynecology at the University Hospitals of Aachen, Jena, Regensburg and Dusseldorf in Germany from 1991 to 2005. For 19 patients, normal breast tissues were available. In all cases, at least two-board certified pathologists agreed on the diagnosis on breast cancer. The samples were recruited in a non-selective, consecutive manner. Cases were not stratified for any known pre-operative or pathological prognostic factor. Inclusion criteria for the study were: Female patients presenting with unilateral, primary invasive breast cancer without individual breast cancer history. Exclusion criteria were: neo-adjuvant chemotherapy prior to surgery, presentation with secondary breast cancer, or peritumorous carcinoma in situ present in the tumor sample. All patients gave informed consent for retention and analysis of their tissue for research purposes and the Institutional Review Boards of the participating centers approved the study. Tumor histology was determined according to the criteria of the WHO (2003), while disease stage was assessed according to UICC [25]. Histological, tumors were graded according to Bloom and Richardson, as modified by Elston and Ellis [26]. Hormone receptor status was assessed according to the scoring system developed by Remmele and Stegner [27]. For 125 patients follow-up data were available with a median time of 64 months (range 1 to 174 months). Patient characteristics of this cohort have been previously described [13].
###end p 16
###begin title 17
Extraction of genomic DNA
###end title 17
###begin p 18
Tumor material was snap-frozen in liquid nitrogen immediately after surgery. Hematoxylin/Eosin-stained sections were prepared for assessing the percentage of tumor cells; only samples with > 70% tumor cells were selected. A total of 20 tissue sections (20 mum each) per specimen was dissected in a cryotom and pooled. Normal breast tissue specimens were prepared likewise. For normal breast samples, the epithelial cell amount had to exceed 30% in order to be selected for further preparation. Samples were dissolved in lysis buffer followed by DNA isolation, using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The extracted genomic DNA was finally diluted in 55 mul of Tris buffer (10 mM; pH 7.6).
###end p 18
###begin title 19
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In silico </italic>
In silico promoter analysis
###end title 19
###begin p 20
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 823 825 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 832 837 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1203 1208 1199 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1298 1300 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1542 1547 1538 1543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1625 1627 1621 1623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1610 1615 <span type="species:ncbi:9606">human</span>
The WIF1 promoter, located at chromosome position 12q14.2, was investigated according to the contig ENSG00000156076 contained in the Ensembl database [28]. A genomic nucleotide sequence consisting of 1000 bp upstream of the annotated transcription start site (TSS) and 293 bp downstream of the TSS (first exon) was analyzed by methprimer software [29]. Criteria for CpG island prediction were adjusted to the definition from Takai and Jones [30], and included an observed/expected CpG ratio of >/= 0.7 and a GC content of >/= 60%. The identified CpG island proximal to the TSS was chosen for promoter methylation analysis. Methylation-specific PCR (MSP) primers were derived from a particular region within this island, which has been analyzed for CpG methylation by bisulfite genomic sequencing (BGS) in a previous study [11]. The DKK3 promoter, located at chromosome position 11p15.3, was investigated according to the contig ENSG00000050165 contained in the Ensembl database. A genomic nucleotide sequence consisting of 1000 bp upstream of the annotated TSS and 1001 bp downstream of the TSS was analyzed by methprimer software. The downstream region covered the first three exons of the gene, since DKK3 was reported to be alternatively transcribed under the control of two distinct promoters [31]. Methprimer software identified the existence of two distinct CpG islands, located proximal to either of the two predicted transcription start sites. The downstream CpG island was chosen for promoter methylation analysis, since the shorter DKK3 transcript was shown to be more commonly distributed in normal human tissues [31].
###end p 20
###begin title 21
Bisulfite-modification and methylation-specific PCR
###end title 21
###begin p 22
###xml 316 321 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 324 326 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 413 414 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 530 532 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 588 590 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 811 815 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
Approximately 1 mug of genomic DNA was bisulfite-modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer's recommendations. The bisulfite-converted DNA was finally eluted in 20 mul of Tris buffer (10 mM; pH 7.6). Methylation-specific PCR was performed according to Herman et al. [32]. In short, 1 mul of modified DNA (~50 ng) was amplified using MSP primers (see Table 1) that specifically recognized either the unmethylated or methylated promoter sequences after bisulfite conversion [32]. Reaction volumes of 25 mul contained 1 x MSP-buffer [33], 400 nM of each primer, and 1.25 mM of each dNTP. One drop of mineral oil was added to each reaction tube. The PCR was initiated as "Hot Start" PCR at 95degreesC and held at 80degreesC before the addition of 1.25 units Taq DNA polymerase (Promega, Madison, WI). Cycle conditions were: 95degreesC for 5 min, 34 cycles of 95degreesC for 30 sec, 55degreesC (58degreesC) for 30 sec, 72degreesC for 40 sec and a final extension at 72degreesC for 5 min. Amplification products were visualized on 3% low range ultra agarose gel (Bio-Rad Laboratories, Hercules, CA) containing ethidium bromide and illuminated under ultraviolet light. Specificity of MSP primers in detecting the promoter methylation status were demonstrated by use of universal unmethylated and universal poly-methylated DNA as template (Epi Tect Control DNA Set; Qiagen, Hilden, Germany). Sensitivity of the utilized primers and cycling conditions was defined by use of a dilution series in MSP assays, constituted of methylated DNA diluted with unmethylated DNA (50%, 10%, 1%, 0.1%, 0.01% and 0% methylation).
###end p 22
###begin p 23
Oligonucleotide primers used in the study
###end p 23
###begin p 24
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
TA, annealing temperature.
###end p 24
###begin title 25
Statistical evaluations
###end title 25
###begin p 26
###xml 118 119 118 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1529 1531 1529 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 1544 1546 1544 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 1560 1562 1560 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 647 655 <span type="species:ncbi:9606">patients</span>
###xml 882 890 <span type="species:ncbi:9606">patients</span>
###xml 1159 1167 <span type="species:ncbi:9606">patients</span>
Statistical analyses were completed using SPSS 14.0 (SPSS, Chicago, IL). Differences were considered significant when P-values were below 0.05. To study statistical associations between clinicopathological factors and methylation status contingency tables and two-sided Fisher's exact test were accomplished. In case of multiple statistical tests, the false discovery rate controlling procedure was applied. Survival curves were calculated using the Kaplan-Meier method, with significance evaluated by two-sided log-rank statistics. OS (n = 125) was measured from the day of surgery until breast cancer-related death (n = 21) and was censored for patients alive at last contact (n = 91), in case of death unrelated to the tumor (n = 5) or when the death cause was unknown (n = 8). DFS (n = 125) was measured from surgery until local or distant relapse (n = 30) and was censored for patients alive without evidence of relapse at the last follow-up (n = 95). A stepwise multivariate Cox regression model was adjusted, testing the independent prognostic relevance of clinical/investigational factors. The limit for reverse selection procedures was p = 0.1. Only patients for whom the status of all variables was known (n = 103) were included in the proportional hazard models. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions. The variables tumor size (pT), node status (pN) and histological grade (G) were dichotomised into less and more progressive groups (pT1-2 vs. pT3-4; pN0 vs. pN1-3; G1-2 vs. G3).
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
WIF1 promoter methylation in primary breast carcinomas
###end title 28
###begin p 29
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 765 770 765 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 911 916 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1096 1101 1096 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1241 1242 1241 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1324 1329 1324 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1426 1427 1426 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1500 1505 1500 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1599 1604 1599 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1742 1744 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 29 34 <span type="species:ncbi:9606">human</span>
WIF1 promoter methylation in human breast cancer has been previously reported by Ai et al. [11], who demonstrated, by use of MSP, WIF1 methylation in 16 of 24 (67%) breast carcinoma samples. For three breast tumor specimens, these MSP results had also been confirmed by BGS. Unfortunately, in their study the WIF1 promoter regions investigated by MSP and BGS were not matching or overlapping, so we decided to analyze WIF1 promoter methylation in breast cancer by MSP in the particular promoter region that has been covered by BGS in the other study (Figure 1A). Initially, a dilution series of methylated DNA in an excess of unmethylated DNA (Epi Tect Control DNA, bisulfite-converted) was tested by MSP. This experiment determined the sensitivity of the utilized WIF1 MSP assay to be 1.0% in the detection of methylated DNA molecules (~0.1 ng) in a background of unmethylated DNA (~9.9 ng) (Figure 1B). Next, WIF1 promoter methylation was determined by MSP in 150 primary breast carcinoma specimens and also in 19 matching normal breast tissues. In all normal breast tissues, only unmethylated WIF1 promoter sequence could be detected, as indicated by exclusive amplification with primers recognizing the unmethylated DNA sequence (Figure 2). In contrast, 95 of 150 primary breast carcinomas (63.3%) revealed a methylated WIF1 promoter sequence, as indicated by amplification with primers specific to methylated DNA (Figure 2). The remaining 55 tumor specimens (36.7%) revealed solely unmethylated WIF1 promoter sequence. In general, tumor samples, despite methylation, also revealed unmethylated WIF1 promoter sequence, which is likely due to small contaminations with stromal and endothelial cells, as has also been previously described [34].
###end p 29
###begin p 30
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Methylation analysis of the human <italic>WIF1 </italic>promoter</bold>
###xml 50 51 50 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 87 92 87 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 414 415 414 415 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 630 635 630 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
Methylation analysis of the human WIF1 promoter. (A) A 1.29 kb genomic sequence of the WIF1 promoter, analyzed by methprimer software [29], revealed the presence of a CpG island (blue) between relative position 604 and 1153. Position 1000 indicates the transcription start site (TSS, arrow). A region of high CpG (red vertical bars) densitiy was chosen for MSP analysis. The black bar indicates the MSP amplicon. (B) Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA (Epi Tect control DNA, Qiagen). At least 1% of methylated DNA (~0.1 ng) can be detected with the WIF1 MSP primers. bp, base pair marker; NTC, 'no template control'.
###end p 30
###begin p 31
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>WIF1 </italic>methylation in primary breast cancer</bold>
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 988 993 988 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 981 987 <span type="species:ncbi:8164">Suzuki</span>
WIF1 methylation in primary breast cancer. WIF1 methylation analyses of primary breast cancer specimens. MSP was performed on bisulfite-treated DNA from breast cancer (T) and matching normal primary breast tissues (N). MSP results from three representative matched pairs and eight additional breast carcinomas (#) are shown. DNA bands in lanes labeled with U indicate MSP products amplified with primers recognizing the unmethylated promoter sequence. DNA bands in lanes labeled with M represent amplified MSP products with methylation-specific primers. Peripheral blood lymphocytes (PBL) and breast cancer cell line ZR75-1 served as positive controls for the methylation-specific reaction, respectively. Water was used as template in the 'no template control' (NTC). Note that tumor tissue usually displayed a PCR product in the U-reaction as well, due to contaminating normal tissue (stromal cells, endothelial cells) present in the tumor specimens as has also been described by Suzuki et al. [34].
###end p 31
###begin title 32
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
DKK3 promoter methylation in primary breast carcinomas
###end title 32
###begin p 33
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
We have recently reported of frequent DKK3 promoter methylation in human breast cancer [13]. In the respective report, we have demonstrated that DKK3 methylation was present in 61.3% of breast cancer patients (92 of 150), whereas in 19 matching normal breast tissues only one sample (5.3%) revealed faint methylation signals. Ideally, the samples analyzed for WIF1 methylation in the present report were physically identical with the samples previously analyzed for DKK3 methylation. The previously analyzed DKK3 promoter region is pictured in Figure 3A. To allow a direct comparison between methylation of these two genes, we first assayed a dilution series of methylated DNA with unmethylated DNA by MSP using DKK3 methylation-specific primers (see above). This experiment determined the sensitivity of the utilized DKK3 MSP assay to be 1.0% in the detection of methylated DNA molecules (~0.1 ng) in a background of unmethylated DNA (~9.9 ng) (Figure 3B), thus enabling a subsequent correlation analysis in breast cancer employing the methylation results from both genes.
###end p 33
###begin p 34
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Methylation analysis of the human <italic>DKK3 </italic>promoter</bold>
###xml 50 51 50 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 311 316 311 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 753 754 753 754 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 969 974 969 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
Methylation analysis of the human DKK3 promoter. (A) A 2.0 kb genomic sequence of the DKK3 promoter, analyzed by methprimer software [29], revealed the presence of two CpG islands (blue); one between relative position 834 and 1261 and another one between position 1529 and 1917. Two alternative tissue-specific DKK3 transcripts have been described [30]. Since transcription of the shorter transcript is widely distributed in normal tissues, we chose the region of the second transcription start site (TSS, arrow) for methylation analysis. Position 1000 indicates the alternative transcription start site of the longer transcript (TSS*, arrow). A region of high CpG (red vertical bars) densitiy within the second CpG island was chosen for MSP analysis. (B) Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA (Epi Tect control DNA, Qiagen). At least 1% of methylated DNA (~0.1 ng) can be detected with the DKK3 MSP primers. bp, base pair marker; NTC, 'no template control'.
###end p 34
###begin title 35
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Association of WIF1 and DKK3 promoter methylation with clinicopathological parameters
###end title 35
###begin p 36
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 503 504 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 195 202 <span type="species:ncbi:9606">patient</span>
###xml 393 400 <span type="species:ncbi:9606">patient</span>
For descriptive data analysis clinicopathological parameters were correlated with the WIF1 and DKK3 promoter methylation status. In a bivariate analysis, WIF1 methylation was not associated with patient age at diagnosis, tumor size, lymph node status, histological grade, histological type, and estrogen or progesterone receptor status (Table 2). DKK3 methylation was associated with advanced patient age at diagnosis (p = 0.007), but not associated with any other of the investigated parameters (Table 2).
###end p 36
###begin p 37
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Demographic/clinicopathological parameters in relation to WIF1 and DKK3 promoter methylation
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
1Only female patients with primary, unilateral invasive breast cancer were included. 2Fisher's exact test. 3According to UICC: TNM Classification of Malignant Tumours [25]. 4IRS, immunoreactivity score according to Remmele and Stegner [27]. Percentages may not sum to 100 due to rounding. IDC, invasive ductal carcinoma; n.a., not available.
###end p 38
###begin title 39
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Correlation of WIF1 and DKK3 promoter methylation in primary breast carcinoma
###end title 39
###begin p 40
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 376 381 376 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 510 515 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 545 550 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
In a bivariate analysis, methylation of the WIF1 promoter was significantly associated with methylation of the DKK3 promoter (p = 0.009) (Table 2). Both gene promoters were mutually unmethylated in tumors from 29 of 150 patients (19.3%) and mutually methylated in tumors from 66 of 150 patients (44.0%) (Figure 4). For 55 of 150 patients (36.7%) the methylation status of the WIF1 and DKK3 promoter differed: WIF1 methylation together with DKK3 non-methylation was detected in 29/250 patients (19.3%), whereas WIF1 non-methylation together with DKK3 methylation was detected in 26 of 150 patients (17.3%).
###end p 40
###begin p 41
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 79 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation in primary breast carcinomas</bold>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
Distribution of WIF1 and DKK3 promoter methylation in primary breast carcinomas. Methylation status of either gene has been determined by MSP in the same tumors. Of n = 150 breast cancer patients, the larger fraction reveals an identical methylation status of both genes (63.3%). In the remaining smaller fraction (36.6%), methylation of only one of the two genes could be detected. In total, WIF1 methylation was significantly associated with DKK3 methylation (p = 0.009; Fisher's exact test).
###end p 41
###begin title 42
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 46 53 <span type="species:ncbi:9606">patient</span>
Association of WIF1 promoter methylation with patient survival
###end title 42
###begin p 43
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 176 181 176 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 353 354 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 231 238 <span type="species:ncbi:9606">patient</span>
###xml 257 264 <span type="species:ncbi:9606">patient</span>
Patient OS and DFS were compared between methylated versus unmethylated WIF1 promoter sequence by univariate Kaplan-Meier analysis using log-rank statistics. In this analysis, WIF1 methylation was not significantly associated with patient OS (p = 0.656) or patient DFS (p = 0.154) (Table 3), as also demonstrated by Kaplan-Meier survival curves (Figure 5). As expected, a positive lymph node status (pN1-3) and higher histological grade (G3) were found to be associated with decreased OS (p = 0.002; p = 0.001) and DFS (p < 0.001; p = 0.012).
###end p 43
###begin p 44
Univariate survival analysis of clinicopathological and molecular factors (log-rank test)
###end p 44
###begin p 45
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 101 102 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
1Only female patients with primary, unilateral invasive breast cancer were included. 2Log-rank test. 3According to UICC: TNM Classification of Malignant Tumours [25]. 4IRS, immunoreactivity score according to Remmele and Stegner [27]. IDC, invasive ductal carcinoma.
###end p 45
###begin p 46
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 0 117 0 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Univariate Kaplan-Meier survival analysis of breast cancer patients in relation to <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation</bold>
###xml 120 121 120 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 145 146 145 146 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 326 331 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 355 356 355 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 639 640 639 640 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D</bold>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 223 228 <span type="species:ncbi:9606">human</span>
###xml 474 481 <span type="species:ncbi:9606">patient</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
###xml 868 876 <span type="species:ncbi:9606">patients</span>
Univariate Kaplan-Meier survival analysis of breast cancer patients in relation to WIF1 and DKK3 promoter methylation. (A) Overall survival and (B) disease-free survival are not associated with WIF1 promoter methylation in human breast cancer. Solid lines indicate methylated WIF1 promoter; dotted lines indicate unmethylated WIF1 promoter in the tumor. (C) In contrast, methylation of the DKK3 promoter in tumor tissue (solid line) is significantly associated with adverse patient overall survival, whereas patients with an unmethylated DKK3 promoter in the tumor tissue have a very favorable clinical outcome (dotted line) (p < 0.001). (D) In addition, DKK3-methylated tumors reveal a significant shorter time to recurrence (solid line), as compared to tumors harboring an unmethylated DKK3 promoter (dotted line) (p = 0.037). Vertical tick marks represent censored patients.
###end p 46
###begin title 47
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 46 53 <span type="species:ncbi:9606">patient</span>
Association of DKK3 promoter methylation with patient survival
###end title 47
###begin p 48
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 244 246 244 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 311 313 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 413 415 413 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 480 482 480 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 919 924 919 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1029 1034 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1228 1233 1228 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1331 1336 1331 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1403 1404 1403 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1415 1416 1415 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1432 1437 1432 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1575 1576 1575 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1612 1617 1612 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1697 1698 1697 1698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
###xml 902 910 <span type="species:ncbi:9606">patients</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
###xml 1271 1278 <span type="species:ncbi:9606">patient</span>
###xml 1365 1372 <span type="species:ncbi:9606">patient</span>
Patient OS and DFS were compared between methylated versus unmethylated DKK3 promoter sequence. In contrast to WIF1 methylation, DKK3 methylation was significantly associated with poor OS (5-year survival: 75% for cases with methylated alleles vs. 97% for cases with unmethylated alleles; 10-year survival: 54% vs. 97%; p = 0.0005; Table 3) and shorter DFS (5-year survival: 67% for cases with methylated alleles vs. 84% for cases with unmethylated alleles; 10-year-survival: 58% vs. 78%; p = 0.037; Table 3), as also illustrated by Kaplan-Meier survival curves (Figure 5). Based on a mean OS of 141 months (95% CI: 127-154 months) patients without DKK3 methylation in the tumor tissue revealed much longer mean OS (170 months, 95% CI: 163-177 months) than patients with DKK3 methylation in the tumor tissue (113 months, 95% CI: 95-131 months). Based on a mean DFS of 99 months (95% CI: 90-107 months) patients without DKK3 methylation in the tumor revealed longer mean DFS (110 months, 95% CI: 99-122 months) than patients with DKK3 methylation in the tumor (86 months, 95% CI: 75-97 months). Multivariate Cox regression models were calculated and adjusted to assess factor-related hazard risks and to test for independency of DKK3 methylation as a prognostic factor in patient OS and DFS. The strength of the association between DKK3 methylation and unfavourable patient outcome is presented in Table 4 and Table 5. Multivariate, DKK3 methylation in breast carcinoma represented an independent and strong risk factor for OS (HR: 14.4; 95% CI: 1.9 - 111.6; p = 0.011; Table 4). In DFS the prognostic potency of DKK3 methylation was weaker than in OS (HR: 2.5; 95% CI: 1.0 - 6.0; p = 0.047; Table 5).
###end p 48
###begin p 49
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Multivariate Cox regression analysis of DKK3 promoter methylation with regard to overall survival
###end p 49
###begin p 50
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
1Confidence interval (CI) on the estimated hazard ratio (HR). 2Only terms that remained in the model after reverse selection are listed. All variables were stratified binary according to Table 3.
###end p 50
###begin p 51
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
Multivariate Cox regression analysis of DKK3 promoter methylation with regard to disease-free survival
###end p 51
###begin p 52
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 62 63 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
1Confidence interval (CI) on the estimated hazard ratio (HR). 2Only terms that remained in the model after reverse selection are listed. All variables were stratified binary according to Table 3.
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 387 389 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 496 498 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 641 646 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 656 658 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 770 775 767 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 911 916 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 919 921 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 960 965 957 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1462 1464 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1489 1491 1483 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1505 1507 1499 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1522 1526 1516 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1</italic>
###xml 1532 1537 1526 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1636 1639 1630 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g</italic>
###xml 1687 1689 1681 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1690 1692 1684 1686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1693 1695 1687 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1804 1809 1798 1803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1925 1927 1919 1921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 2092 2097 2086 2091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 1993 2001 <span type="species:ncbi:9606">patients</span>
It was previously reported that expression of the Wnt antagonist genes WIF1 and DKK3 is downregulated in several tumor entities as a consequence of epigenetic DNA modification [11,13,21,31,35,36]. WIF1 is a conserved Wnt-binding protein that prevents Wnt ligands from interacting with membranous frizzled receptors, thus may inhibit activation of the Wnt/beta-catenin signaling cascade [37]. In breast, lung, prostate and bladder cancer, WIF1 expression was found to be frequently downregulated [38], suggesting it might represent a tumor suppressor gene. In breast cancer, this downregulation could be attributed to hypermethylation of the WIF1 promoter [11], as demonstrated both in breast cell lines and in primary breast carcinomas. In our study, methylation of the WIF1 promoter was detected in 63% of invasive tumors from breast cancer patients, thus being in good agreement with previous results from Ai et al. [11], who reported a frequency of 67% for WIF1 methylation in mammary tumors. Differences may arise through different sample sizes (n = 150 and n = 24) as well as different promoter locations assessed in either study. DKK3 is a further secreted inhibitor of Wnt signaling, but in contrast to WIF1 does not sequester Wnt ligands. The actual mechanism by which DKK3 acts inhibitory on Wnt pathway activation has not been identified yet, but suppression of DKK3 increased beta-catenin/T-cell factor (TCF)-dependent gene activity in mammary cells [39], cancerous lung cells [40] and glioma [41]. Likewise to WIF1, the DKK3 gene was also reported as a frequent target of epigenetic inactivation in numerous tumor entities, e.g. in lung cancer, prostate cancer and leukemia [21,31,42], suggesting that DKK3 may exert tumor suppressive functions. In a recent report, we have demonstrated that DKK3 is frequently inactivated in invasive breast carcinomas by promoter methylation leading to loss of DKK3 expression [13]. This epimutation affected 92 of 150 investigated breast cancer patients (61%). Since these samples were identical to the samples for which we now have determined WIF1 methylation, we were able to perform a combined analysis of both genes' methylation in breast cancer.
###end p 54
###begin p 55
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 469 479 469 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3/WIF1 </italic>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1052 1057 1052 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 1060 1065 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
###xml 792 799 <span type="species:ncbi:9606">patient</span>
In a bivariate analysis, WIF1 methylation status in breast carcinomas was significantly associated with the DKK3 methylation status. Despite, within the cohort of carcinomas being affected by methylation of either the DKK3 or WIF1 gene, a large fraction (45%) showed methylation in one gene only. This demonstrates that in spite of a statistical association between methylation of the two genes, there is still a large fraction of breast cancer patients with different DKK3/WIF1 methylation pattern. Therefore, it is unlikely that methylation of both Wnt antagonist genes is a mandatory mutual carcinogenic event. In a further correlation analysis, neither of the two genes was associated with relevant clinicopathological features, except for DKK3 methylation being associated with advanced patient age. Age-dependent promoter methylation has been reported previously [43,44] and may randomly overlay the effects of gene-specific promoter methylation that can lead to the development of distinct cancer subtypes. The absence of an association between WIF1 or DKK3 methylation with important clinicopathological factors like tumor size, histological grade and lymph node invasion strongly suggests that methylation of either gene is an early carcinogenic event in breast cancer development, rather than contributing to tumor progression.
###end p 55
###begin p 56
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 474 479 474 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 626 630 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 794 797 794 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">i.e</italic>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1288 1290 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1358 1363 1358 1363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1520 1525 1520 1525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 1697 1699 1697 1699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1700 1702 1700 1702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 184 191 <span type="species:ncbi:9606">patient</span>
###xml 275 282 <span type="species:ncbi:9606">patient</span>
###xml 326 334 <span type="species:ncbi:9606">Patients</span>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
###xml 778 785 <span type="species:ncbi:9606">patient</span>
###xml 1221 1229 <span type="species:ncbi:9606">patients</span>
###xml 1482 1490 <span type="species:ncbi:9606">patients</span>
Most important, major differences between WIF1 and DKK3 methylation arise in their association with breast cancer patient survival. WIF1 methylation showed no significance in clinical patient outcome in contrast to DKK3 methylation, which was tightly associated with adverse patient OS and weaker with short DFS in our study. Patients harboring DKK3 methylation in the tumor had a poor prognosis (54% chance of 10-years OS) in contrast to patients retaining an unmethylated DKK3 promoter, who had a favorable prognosis (97% chance of 10-years OS). This finding was supported by a multivariate Cox regression analysis in which DKK3-methylated patients revealed a high risk of tumor-related death (HR: 14.4). Hence, this parameter outperformed classical prognostic factors in our patient cohort, i.e. high histological grade (HR: 4.4) or a positive lymph node status (HR: 5.5). Unproportional HRs of high impact were rarely achieved even in studies with very large sample size numbers, neither by strong conventional factors like node status (HR: 2.4) [45] and grade (HR: 5.7) [46] nor by investigational factors like the tissue urokinase-type plasminogen activator/inhibitor (uPA/PAI), which in case of high level exposes patients to a five times greater risk of dying from breast cancer [47]. In conclusion, our results demonstrate that determination of the DKK3 methylation status may provide valuable information to aid prognostication in the clinical management of breast cancer patients. Notably, methylation of the DKK3 promoter was recently shown to be prognosis relevant also in other tumor entities, such as in acute lymphoblastic leukemia, kidney cancer, lung cancer, and gastric cancer [21-24], pointing to a potential clinical use of this marker in several cancer diseases.
###end p 56
###begin p 57
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 623 625 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 458 466 <span type="species:ncbi:9606">patients</span>
Our findings raise expectations towards translation of such methylation markers into clinical practice. As an example, DKK3 may be a prime candidate gene to be incorporated into diagnostic multimarker panels, for its aberrant methylation is specific to malignant cells in breast cancer [13]. Preliminary results from our laboratory revealed that DKK3 methylation can be detected with high clinical sensitivity and specificity in blood serum of breast cancer patients independent of tumor size and node status (unpublished data). The presence of detectable tumor DNA in serum is generally associated with poor prognosis [48,49], and taken together with its marker performance in solid breast tumor tissue, DKK3 methylation fulfils essential prerequisites as a biomarker in a blood-borne assay, of which we will report in a future study.
###end p 57
###begin p 58
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 310 317 <span type="species:ncbi:9606">patient</span>
In summary, we here demonstrate that although WIF1 and DKK3 promoter methylation are similar frequent alterations in human breast cancer, only DKK3 methylation appears to be a survival risk factor for breast cancer patients and thus might be useful as prognostic marker in clinical oncology helping to improve patient outcome.
###end p 58
###begin title 59
Conclusion
###end title 59
###begin p 60
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3</italic>
###xml 303 308 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
###xml 399 404 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WIF1 </italic>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 373 380 <span type="species:ncbi:9606">patient</span>
This study shows that the Wnt antagonist gene WIF1 is frequently inactivated by promoter hypermethylation in human breast cancer. Although WIF1 is similarly frequent hypermethylated like the Wnt antagonist gene DKK3, and neither gene methylation is associated with relevant clinicopathological factors, DKK3 methylation is an independent prognostic factor in breast cancer patient survival, whereas WIF1 methylation is not. These differences may reflect subtle distinctions in the biological roles of the two related molecules in inhibiting Wnt/beta-catenin signaling.
###end p 60
###begin title 61
Abbreviations
###end title 61
###begin p 62
BGS: bisulfite genomic sequencing; BMBF: Bundesministerium fur Bildung und Forschung; CI: confidence interval; DFS: disease-free survival; DKK3: Dickkopf-3; ER: estrogen receptor; HR: hazard ratio; MSP: methylation-specific polymerase chain reaction; NTC: no template control; OS: overall survival; PCP: planar cell polarity pathway; PCR: polymerase chain reaction; PR: progesterone receptor; TCF: T-cell factor; UICC: International Union Against Cancer; UMD: universal methylated DNA; UUD: universal unmethylated DNA; WHO: World Health Organization; WIF1: Wnt-inhibitory factor 1.
###end p 62
###begin title 63
Competing interests
###end title 63
###begin p 64
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DKK3 </italic>
ED has declared that he has submitted a patent application on the use of DKK3 promoter methylation. The other authors declare that they have no competing interests.
###end p 64
###begin title 65
Authors' contributions
###end title 65
###begin p 66
JV carried out the methylation experiments, contributed to statistical evaluations, participated in the conception and design of the study, and wrote the manuscript. PJW participated in statistical analyses and data interpretation, and critically revised the manuscript. TF and PJS supported with expertise in statistical analyses, and critically revised the manuscript. AH provided clinical samples and clinicopathological data, and critically revised the manuscript. RK participated in the design and coordination of the study, and critically revised the manuscript. ED planned and coordinated the study, and critically revised the manuscript. All authors have given final approval of the version to be published.
###end p 66
###begin title 67
Pre-publication history
###end title 67
###begin p 68
The pre-publication history for this paper can be accessed here:
###end p 68
###begin p 69

###end p 69
###begin title 70
Acknowledgements
###end title 70
###begin p 71
###xml 280 287 <span type="species:ncbi:9606">patient</span>
###xml 508 513 <span type="species:ncbi:9606">Human</span>
The expert technical assistance of Sevim Alkaya, Sonja von Serenyi and Inge Losen is greatly appreciated. We thank Dr. Dieter Niederacher (Heinrich-Heine University, Dusseldorf, Germany) and Prof. Matthias Durst (Friedrich-Schiller University, Jena, Germany) for kindly providing patient samples as well as Dr. Monika Klinkhammer-Schalke and Dr. Felicitas Horn (Tumour Registry, Regensburg, Germany) for continuous help in obtaining clinical follow-up data. This work is a research project within the German Human Genome Project and has been supported by the BMBF grant 01KW0401 to ED.
###end p 71
###begin article-title 72
###xml 35 40 <span type="species:ncbi:9606">human</span>
A gene hypermethylation profile of human cancer
###end article-title 72
###begin article-title 73
DNA methylation and breast carcinogenesis
###end article-title 73
###begin article-title 74
###xml 26 31 <span type="species:ncbi:9606">human</span>
Epigenetic biomarkers for human cancer: The time is now
###end article-title 74
###begin article-title 75
Wnt signaling and breast cancer
###end article-title 75
###begin article-title 76
###xml 58 63 <span type="species:ncbi:9606">human</span>
Epigenetic alterations of the Wnt/beta-catenin pathway in human disease
###end article-title 76
###begin article-title 77
Somatic mutations of the APC gene in primary breast cancers
###end article-title 77
###begin article-title 78
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis
###end article-title 78
###begin article-title 79
###xml 84 89 <span type="species:ncbi:9606">human</span>
Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer
###end article-title 79
###begin article-title 80
###xml 114 119 <span type="species:ncbi:9606">human</span>
Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer
###end article-title 80
###begin article-title 81
###xml 83 88 <span type="species:ncbi:9606">human</span>
Epigenetic inactivation of the Secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis
###end article-title 81
###begin article-title 82
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer
###end article-title 82
###begin article-title 83
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer
###end article-title 83
###begin article-title 84
###xml 18 23 <span type="species:ncbi:9606">human</span>
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours
###end article-title 84
###begin article-title 85
Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers
###end article-title 85
###begin article-title 86
Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas
###end article-title 86
###begin article-title 87
Identification of novel high-frequency DNA methylation changes in breast cancer
###end article-title 87
###begin article-title 88
Diagnostic and therapeutic applications of epigenetics
###end article-title 88
###begin article-title 89
Methylation changes in faecal DNA: a marker for colorectal cancer screening?
###end article-title 89
###begin article-title 90
Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions
###end article-title 90
###begin article-title 91
SFRP2 methylation in fecal DNA-a marker for colorectal polyps
###end article-title 91
###begin article-title 92
Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia
###end article-title 92
###begin article-title 93
Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA
###end article-title 93
###begin article-title 94
Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer
###end article-title 94
###begin article-title 95
Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer
###end article-title 95
###begin article-title 96
Method for grading breast cancer
###end article-title 96
###begin article-title 97
Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue
###end article-title 97
###begin article-title 98
Ensembl Genome Browser
###end article-title 98
###begin article-title 99
MethPrimer: designing primers for methylation PCRs
###end article-title 99
###begin article-title 100
###xml 41 46 <span type="species:ncbi:9606">human</span>
Comprehensive analysis of CpG islands in human chromosomes 21 and 22
###end article-title 100
###begin article-title 101
###xml 74 79 <span type="species:ncbi:9606">human</span>
Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells
###end article-title 101
###begin article-title 102
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 102
###begin article-title 103
Methylation-specific polymerase chain reaction
###end article-title 103
###begin article-title 104
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
###end article-title 104
###begin article-title 105
###xml 68 73 <span type="species:ncbi:9606">human</span>
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer
###end article-title 105
###begin article-title 106
###xml 63 68 <span type="species:ncbi:9606">human</span>
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers
###end article-title 106
###begin article-title 107
A new secreted protein that binds to Wnt proteins and inhibits their activities
###end article-title 107
###begin article-title 108
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer
###end article-title 108
###begin article-title 109
Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways
###end article-title 109
###begin article-title 110
Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer
###end article-title 110
###begin article-title 111
###xml 33 38 <span type="species:ncbi:9606">human</span>
REIC/Dkk-3 induces cell death in human malignant glioma
###end article-title 111
###begin article-title 112
Functional epigenomics identifies genes frequently silenced in prostate cancer
###end article-title 112
###begin article-title 113
Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples
###end article-title 113
###begin article-title 114
Age-dependent methylation of ESR1 gene in prostate cancer
###end article-title 114
###begin article-title 115
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer
###end article-title 115
###begin article-title 116
Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study
###end article-title 116
###begin article-title 117
Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis
###end article-title 117
###begin article-title 118
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations
###end article-title 118
###begin article-title 119
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis
###end article-title 119

